Monteverde & Associates PC is investigating the fairness of merger deals involving Utz Brands, Safety Insurance Group, Passage Bio, and Finward Bancorp. Shareholders of these companies are offered specific cash or stock deals, and the firm is assessing whether these offers are fair. The investigation is free for shareholders and aims to protect their interests by potentially recovering additional value. Investors are encouraged to contact the firm for more information and legal support if needed.
The shareholder alert on merger fairness investigations involving Utz Brands, Safety Insurance Group, Passage Bio, and Finward Bancorp provides context for readers. For those following the Financials sector, here is Pluang's market snapshot as of Oct 21, 2026 04:11 WIB: out of 142 priced Financials-sector US stocks, 118 rose and 23 fell today. Notable movers include FITB at USD 52.63 with 0% Sell / 100% Buy Pluang order activity and a typical hold time of 6 days, WULF at USD 12.56 with 51% Sell / 49% Buy activity and a 19-day hold time, and FNB at USD 17.65 with a 6-day typical hold time.
Medical Informatics Corp. has launched the Sickbay Experience Demo Center at Texas Medical Center's Helix Park, showcasing its FDA-cleared Sickbay platform. This interactive center demonstrates how real-time patient data from various medical devices ...
Grupo Aeroportuario del Pacífico reported Q3 2026 earnings per share of $2.66 and revenue of $632.9 million, both below analyst expectations. Despite the miss, the company saw a 13.2% rise in revenue excluding construction services and a 19.2% increa...
Northern Trust is set to report its Q3 2026 earnings with analysts forecasting a 24.9% rise in earnings per share to $2.86 and an 11.8% increase in revenue to $2.26 billion. Growth is driven by an 11.4% increase in net interest income and a 12.1% ris...
Moody's is expected to report Q3 2026 earnings of around $4.25 per share on revenue near $2.08 billion, driven by steady demand for credit ratings and growth in Moody's Analytics, especially from recurring subscriptions and AI tools. While Moody's In...
Raymond James increased its price target for Rapport Therapeutics to $86 following positive Phase 2 trial results of RAP-219, a drug treating acute bipolar mania. The trial showed statistically significant improvement in patients and a favorable safe...
